Status:
COMPLETED
Etoposide-Carboplatin Alone or With Endostar for Extensive Disease Small Cell Lung Cancer (ED-SCLC)
Lead Sponsor:
Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd
Conditions:
Small Cell Lung Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
Background: The effect of existing treatment modalities of extensive disease small-cell lung cancer (ED-SCLC) is unsatisfactory. Progress of new strategies including more efficient therapy is wanted....
Detailed Description
Methods: In this randomized, open label, placebo-controlled, multicentre trial, 120 patients are planned to be enrolled at random into 2 arms(1:1) from 10 centers between June 2009 and June 2011. The...
Eligibility Criteria
Inclusion
- Histologically or cytologically diagnosed SCLC;
- Age of 18-75 years;
- Life expectancy \> 3 months;
- Adequate hematologic, renal, and hepatic function;
- ECOG PS 0-2;
Exclusion
- Brain metastases;
- Clinically significant cardiovascular disease;
- Presence of hepatic and renal dysfunction;
- Evidence of bleeding diathesis or coagulopathy
- Pregnant or lactating woman;
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
138 Patients enrolled
Trial Details
Trial ID
NCT00912392
Start Date
May 1 2009
End Date
December 1 2012
Last Update
September 3 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China, 200039